Is there a place for tricyclic antidepressants and subsequent augmentation strategies in obtaining remission for patients with treatment resistant depression?

Gervasoni, Nicola Gérard; Aubry, Jean-Michel; Gex-Fabry, Marianne; Bertschy, Gilles; Bondolfi, Guido

doi:10.1016/j.phrs.2008.11.005

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		Is there a place for tricyclic antidepressants and subsequent augmentation strategies in obtaining remission for patients with treatment resistant depression?
Authors		Gervasoni, Nicola Gérard Aubry, Jean-Michel Gex-Fabry, Marianne Bertschy, Gilles Bondolfi, Guido
Published in		Pharmacological Research. 2009, vol. 59, no. 3, p. 202-206
Abstract		Major depressive disorder is a worrying mental health problem and obtaining remission from treatment resistant depression (TRD) remains an important clinical issue. Twenty patients (14 women, 6 men) considered as treatment resistant after the fourth step of a seven-step treatment algorithm to obtain remission in major depression received clomipramine 150 mg/day for 1 month (step 5). In case of failure, two subsequent augmentation strategies with lithium and lithium plus triiodothyronine (T3) were implemented. Median Montgomery-Asberg Depression Rating Scale (MADRS) score at initiation of clomipramine treatment was 29 (range 8-43). Treatment with clomipramine alone allowed five patients to achieve sustained remission (MADRS ≤ 8), while three patients were responders (MADRS decrease ≥ 50%) and three patients were partial responders (MADRS decrease > 25%). Lithium augmentation in 10 patients led to one additional remission, whereas no additional remission was observed in 6 patients with further T3 augmentation. Tricyclic antidepressants have demonstrated efficacy in TRD. The present study suggests that treatment with clomipramine might allow obtaining remission in some patients who do not fully respond despite multiple interventions.
Keywords		Adult — Antidepressive Agents, Tricyclic/therapeutic use — Clomipramine/therapeutic use — Depressive Disorder, Major/drug therapy — Drug Resistance — Female — Humans — Lithium Compounds/therapeutic use — Male — Middle Aged — Psychiatric Status Rating Scales — Triiodothyronine/*therapeutic use
Identifiers		DOI: 10.1016/j.phrs.2008.11.005 PMID: 19073260
Full text		Article - Limited access to UNIGE Other version: http://pdn.sciencedirect.com/science?_ob=MiamiImageURL&_cid=272488&_user=9565874&_pii=S1043661808002168&_check=y&_ori...
Structures		Faculté de médecine / Section de médecine clinique / Département de psychiatrie
Research groups		Thérapeutiques des Troubles de l'Humeur et Anxieux (689) Médecine psychosomatique, neurosciences cliniques et mindfulness (690)
Citation (ISO format)		GERVASONI, Nicola Gérard et al. Is there a place for tricyclic antidepressants and subsequent augmentation strategies in obtaining remission for patients with treatment resistant depression?. In: Pharmacological Research, 2009, vol. 59, n° 3, p. 202-206. doi: 10.1016/j.phrs.2008.11.005 https://archive-ouverte.unige.ch/unige:19831

389 hits

0 download

Contact an author

Update request

Update

Deposited on : 2012-04-23

Export document

Format	:
Citation style	:

Archive ouverte UNIGE

Is there a place for tricyclic antidepressants and subsequent augmentation strategies in obtaining remission for patients with treatment resistant depression?